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abstractBACKGROUND AND OBJECTIVES: Community pharmacies may be positioned for an increased role in
population health. We sought to develop a population-level measure of asthma medication fills
and assess its relationship to asthma-related utilization.
METHODS: We conducted a retrospective, ecological study (2010–2012). Medication data from
a chain of pharmacies (n = 27) within 1 county were used to calculate a Pharmacy-level
Asthma Medication Ratio (Ph-AMR), defined as controller fills divided by controller plus
rescue fills. Higher values are superior because they indicate more controller compared with
rescue fills. The outcome was the asthma-related utilization rate among children in the same
census tract as the pharmacy, calculated by dividing all emergency visits and hospitalizations
by the number of children in that tract. Covariates, including ecological measures of
poverty and access to care, were used in multivariable linear regression.
RESULTS: Overall, 35 467 medications were filled. The median Ph-AMR was 0.53 (range
0.38–0.66). The median utilization rate across included census tracts was 22.4 visits per 1000
child-years (range 1.3–60.9). Tracts with Ph-AMR ,0.5 had significantly higher utilization
rates than those with Ph-AMR $0.5 (26.1 vs 9.9; P = .001). For every 0.1 increase in Ph-AMR,
utilization rates decreased by 9.5 (P = .03), after adjustment for underlying poverty and access.
Seasonal variation in fills was evident, but pharmacies in high-utilizing tracts filled more
rescue than controller medications at nearly every point during the study period.
CONCLUSIONS:Ph-AMR was independently associated with ecological childhood asthma morbidity.
Pharmacies may be a community-based leverage point for improving population-level
asthma control through targeted interventions.
WHAT’S KNOWN ON THIS SUBJECT: Disparities in
asthma morbidity are exacerbated by
underutilization of preventive controller
medications. Community pharmacies are well
positioned for an increased role in population
health. The Asthma Medication Ratio, currently
used at the patient-level, could be adapted for
use at the pharmacy-level.
WHAT THIS STUDY ADDS: A newly developed
Pharmacy-level Asthma Medication Ratio was
associated with population-level childhood asthma
morbidity. Collaborative relationships between
physicians, community pharmacists, and patients
(and families) have the potential to promote
testable interventions aimed at reducing asthma
morbidity and cross-community disparities.
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Although asthma is the most common
chronic illness of childhood, the
disease in experienced in different
ways.1–3 Asthma morbidity is
especially common among those
living with poverty and limited
access.4–6 Disparities are perpetuated
by chronic underutilization of
medications that can prevent asthma
symptoms.7–11 Underutilization
results from underprescribing by
providers, underavailability of
medications at pharmacies, and
nonadherence by patients.12–15
Excess morbidity resulting from
underuse of proven, evidence-based
asthma controller medications puts
undue strain on patients,
communities, and the health care
system.
Pharmacies are well positioned for an
increased role in population health
management. Collaborative
relationships between physicians and
community pharmacists could
enhance utilization of asthma
therapies and improve outcomes for
those at highest risk.16–18 As front-
line members of the health care
delivery system, pharmacies and
pharmacists offer the advantage of
both consistent patient interaction
and the ability to track prescription
data over time. Existing provider- and
patient-level measures could be
translated for use by pharmacies to
gauge community-level adherence to
evidence-based asthma care.19–21
Moreover, tracking medication fills
could highlight ways in which
pharmacies could deliver proactive,
as opposed to reactive, asthma
care.22,23 New or redesigned
processes could benefit from novel
performance measures that illustrate
the quality of care that reaches
patients.24
Ultimately, we hope to grow
collaborative, cross-institutional, and
community-based interventions
aimed at reducing asthma morbidity
and disparities. As a first step, we
sought to bring together hospital-
based utilization data and
prescription medication fill data from
in-county pharmacies managed by
a single nationwide chain. Specifically,
using the established Asthma
Medication Ratio (AMR) as a guide, we
sought to calculate a Pharmacy-level
AMR (Ph-AMR) and assess its
relationship with community-level
asthma morbidity. We then sought to
illustrate how asthma-related
controller and rescue medication fills
at participating pharmacies varied
over both time and place (ie, across
low- and high-morbidity communities)
to more effectively identify when and
where promotion of controller
medication distribution could occur.
METHODS
Study Design
We conducted a retrospective
analysis using 2 distinct data sets,
1 from a large, academic children’s
hospital and 1 from a single chain of
retail pharmacies. The 2 data sets
provided information on the same
geographic region; however, they
were not able to be linked at the
patient level.
The hospital-based data set included
children, aged 2 to 17 years, who
visited the emergency department
(ED) or were hospitalized for asthma
at Cincinnati Children’s Hospital
Medical Center (CCHMC) facilities
between January 31, 2010, and
January 30, 2012. Subjects were
identified using asthma-specific
diagnoses (International Classification
of Diseases, ninth Revision, Clinical
Modification 493.XX).25 Children
living outside of Hamilton County,
Ohio, were excluded. Ohio Hospital
Association data suggest that nearly
95% of in-county asthma-related
hospitalizations occur at CCHMC
facilities.26 ED-related market share
data are less clear, but we expect that
visits to other institutions would be
minimal given CCHMC’s strong
market penetration.
A separate administrative data set
was provided by a single national
retail chain with 27 in-county
pharmacies in 27 distinct census
tracts. Census tracts are relatively
homogenous areas of ∼4000 people
defined by local municipalities and
the US Census.27 The included chain
is among the local leaders for
in-county market share with an
estimated 45% (B. Turner, personal
communication, 2014). This data set
comprised all 35 467 asthma
medications filled for deidentified
children aged 2 to 17 years during the
same time period as the utilization
events. Included medications











medications were inhaled short-
acting b-agonists (albuterol,
levalbuterol).
Calculation of the Ph-AMR
We calculated a Ph-AMR for each
included pharmacy. The Ph-AMR was
calculated similarly to the AMR,
a National Committee for Quality
Assurance measure for patients with
persistent asthma, by dividing all
controller by summed controller and
rescue fills.28 It is generally calculated
over a 1-year period. This yields a ratio
ranging from 0 to 1 where 1 is ideal
(ie, all controller and no rescue fills).
After classifying medications as either
controller or rescue, we calculated
a Ph-AMR for each pharmacy by
dividing all dispensed controller
medications by the sum of all
controller plus all rescue medications.
The resulting Ph-AMR was analyzed,
first as a dichotomous variable,
split at 0.5. This cut point was chosen
given previous evidence at the patient
level demonstrating that an AMR
,0.5 is associated with increased
utilization (eg, ED visitation or
1010 BECK et al
hospitalization) and lower quality of
life.19,21,29,30 Second, we explored
a potential dose effect using quintiles,
placing each pharmacy into 1 of 5
groups based on ascending Ph-AMR.
Finally, Ph-AMR was treated as
a continuous variable.
Outcomes
Our primary outcome was ecological
child asthma morbidity, defined by rates
of asthma utilization for each included
census tract. We opted to use the
population living in the same census
tract as the pharmacy as a proxy for that
pharmacy’s market share. The
pharmacies’ 27 distinct tracts were
composed of a combined 129 161
individuals and 25599 children.27
Asthma utilization rates were
calculated using hospital data. All ED
visits and hospitalizations were
connected to the patient’s home
address at the time of the utilization
event. This address was geocoded
and mapped to the corresponding
2010 census tract. We then divided
the sum of all in-tract utilization
events by the total number of
children, aged 2 to 17 years, living
within that tract. This was converted
to a rate, measured per 1000 children
per year, or per 1000 child-years.
Covariates
Many area-level factors have been
shown to be relevant to asthma
morbidity. To maintain a stable,
parsimonious model, we focused on
both poverty and access to care
because they were seen as
particularly relevant to both
utilization and the filling of
prescribed medications.13 Thus, we
extracted data elements available to
us from the US Census’ 2008–2012
American Community Survey. Poverty
was defined as the percentage of in-
tract individuals living below the
federal poverty line. Limited car
access was defined as the percentage
of tract households with no car.27 As
a further measure of medical care
access, we used the Health Resource
and Services Administration–defined
Medically Underserved Areas
(MUA).31 To ensure that census tracts
were composed of similar age
distributions, we also calculated the
proportion of children within each
tract using data from the 2010 U.S.
Census (number of children aged
2–17 years divided by total tract
population).27 The MUA variable was
binary, whereas each of the other
variables was continuous.
Data Analysis
Descriptive statistics were used to
illustrate demographic characteristics
of patients in the hospital-based data
set and variation in Ph-AMR across
included pharmacies. The Wilcoxon
rank sum test, analysis of variance,
and unadjusted linear regression
models were used to assess bivariate
relationships between categories of
Ph-AMR (dichotomized, in quintiles,
and continuous, respectively) and
tract-level utilization rates, and
covariates. Multivariable linear
regression was then used to assess
associations between the Ph-AMR and
utilization after adjustment for
covariates.
We used time-series analyses to
further assess relationships between
controller and rescue medication fills.
First, we created a chart that depicted
medication fills, by week, across all
pharmacies. Cross-correlation
functions assessed any potential
time-delay or seasonal trend in fills.
A linear mixed model with
autoregressive moving average
covariance structure was applied to
a time-varying Ph-AMR to further
evaluate seasonal effects. We created
2 additional charts, splitting
pharmacies based on the utilization
rate of the tract in which each
pharmacy was located. Fills at
pharmacies in the 13 “healthy” or
“low-utilizing” tracts were on 1 chart
and pharmacies in the 14 “sick” or
“high-utilizing” tracts were on
a second. These charts were used to
assess differences in numbers of
controller and rescue fills over time.
Geocoding and mapping were pursued
using ArcGIS software (version 10.1,
Redlands, CA). Statistical analyses were
performed using SAS software (version
9.3, Cary, NC).
This study was approved by the
CCHMC Institutional Review Board.
RESULTS
During the study period, there were
554 asthma-related ED visits and 203
hospitalizations from the included
census tracts (N = 27). These 757
utilization events involved 474
unique children who were 58% male,
53% African American, and 57%
publicly insured, with a median age of
6.2 years (Table 1). The median
utilization rate across the 27 tracts
was 22.4 events per 1000 child-years
(range 1.3–60.9).
TABLE 1 Data Available for Characteristics of Individual Patients From the 27 Included Census
Tracts That Had an Asthma-Related Emergency Department Visit or Hospital Admission
Between January 31, 2010 and January 30, 2012 (n = 474)
N (or Median) %a (or IQR)
Age (y) 6.2 3.6–10.0
Male gender 277 58.4
Race
Black/African American 249 52.5
White 168 35.4
Other 47 9.9
Unknown or missing 10 2.1




Unknown or missing 14 3.0
a Percentages may not add to exactly 100 due to rounding.
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Included pharmacies dispensed
18 842 controller and 16 625 rescue
medications. There was considerable
variation in Ph-AMR across individual
pharmacies (median Ph-AMR of
0.53, range 0.38–0.66; 10 pharmacies
had a Ph-AMR ,0.5) (Fig 1).
Pharmacies were well distributed
geographically, both in Cincinnati’s
urban core and outlying suburbs
(Fig 2). Across included tracts, the
median percentage of individuals
living below the federal poverty line
was 12.2% (range 2.3%–42.2%). The
median percentage of households
with no car was 8.5% (range
1.5%–25.6%).
Census tracts with pharmacies that
had a Ph-AMR ,0.5 had significantly
higher utilization rates than tracts
with pharmacies that had a Ph-AMR
$0.5 (26.1 vs 9.9 events per 1000
child-years; P = .001). Similarly, low
Ph-AMR tracts had higher rates of
poverty (16.6% vs 8.5%; P = .02) and
households without cars (13.8% vs
6.8%; P = .07). All 3 tracts that were
located in an MUA were also located
in tracts with pharmacies that had
a Ph-AMR ,0.5 (Fisher’s exact test
P , .05).
Ph-AMR quintile was associated with
population-level emergent utilization
rates in a graded fashion (Table 2).
The utilization rate in the group with
the lowest Ph-AMR was 28.4 events
per 1000 child-years; the quintile
with the highest Ph-AMR had
a utilization rate of 7.1 per 1000
children (P = .001). Similar trends
were noted for relationships between
Ph-AMR quintile and poverty and
limited car access (P = .05 and P = .02,
respectively). The proportion of
children did not differ significantly
between included census tracts.
Figure 3 illustrates the linear
relationship between Ph-AMR, on
a continuous scale, and utilization
rates (R2 = 0.45, P , .0001). When
the model included poverty, car
access and MUA, the R2 rose to 0.66,
with the model accounting for 66% of
the variation (Ph-AMR P = .03).
Figure 4 illustrates our time-series
analyses. Dotted lines represent
controller fills, and solid lines
represent rescue medication fills. The
gray lines are weekly data, and the
black lines are 4-week moving
averages. In Fig 4A, we depict
medication fills at all pharmacies.
There is significant variation across
time with peaks of both controller
and rescue medication fills occurring
in spring and fall. The cross-
correlation function of controller and
rescue medication fills illustrates
alignment for the timing of fill peaks
and valleys consistent with the
presumed seasonal variation. A
Ph-AMR calculated at various time
points demonstrates that spring and
summer were found to have
significantly higher Ph-AMR values
than winter (on average, the Ph-AMR
is 2.2% higher in spring, P = .05; and
3.1% higher in summer, P = .005),
suggesting that controllers are filled
more regularly during these seasons.
Figure 4B presents data just for the
13 pharmacies within low-utilizing,
“healthy” tracts (ie, below the
median). Similar seasonal trends are
noted, although the controller line is
FIGURE 1
Ph-AMR for a single chain of 27 Hamilton County, Ohio, pharmacies. Goal of.0.5 extrapolated from what has been found to be optimal at the patient level.
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higher than the rescue line at nearly
all points over time. Figure 4C
presents data for the 14 pharmacies
within census tracts that have
utilization rates above the median.
Here, the rescue line appears higher
than the controller line at nearly all
points. Indeed, pharmacies in
“healthy,” low-utilizing neighborhoods
dispensed more controller
medications; pharmacies in “sick,”
high-utilizing neighborhoods
dispensed more rescue medications
(P , .0001).
DISCUSSION
There is a strong relationship
between a newly developed
pharmacy-level metric that quantifies
the ratio of dispensed asthma
controller and rescue medications
and asthma emergent care utilization.
A 0.1 increase in a pharmacy’s
Ph-AMR was associated with
a reduction of 9.5 events per 1000 in
the corresponding census tract’s
utilization rate. If, in fact, these
relationships are causal, as supported
by the previous literature, improved
Ph-AMR rates, and associated use of
proven controller therapies, would
substantially reduce asthma
morbidity and its associated cost.
Asthma is a manageable chronic illness
with an evidence base highlighting the
positive impact daily controller
medications can have on symptom
prevention. Still, morbidity persists,
disproportionately affecting patients
living in high-poverty and low-access
communities.4 Underutilization of
controllers likely contributes to
observed disparities and is especially
common among underserved
children.9,10,13 Lintzenich et al found
that just 52% of children aged 2 to
18 years were prescribed a controller
medication after discharge from the
hospital—patients who would qualify
for and benefit from such
medications.7 Given that many of these
same patients may not follow up with
a primary care physician,7 alternative
opportunities (and locations) for care
delivery should be explored.
Pharmacies with low Ph-AMRs were
in tracts that had utilization rates
FIGURE 2
Ph-AMR and asthma emergent utilization based on census tract, both measured for time period between January 31, 2010, and January 30, 2012.
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4 times those of pharmacies with
high Ph-AMRs. Likewise, pharmacies
in high-morbidity tracts dispensed
more rescue than controller
medications at nearly all points over
the study period. Given their
expertise and in-community location,
pharmacies are well positioned to
facilitate evidence-based
management of chronic asthma,
especially within communities at
highest risk. Indeed, collaborations
between hospitals and pharmacies,
physicians and pharmacists, would
be an important step toward the
development and testing of potential
interventions aimed at improving
care delivery and avoiding or
preventing of emergent care visits.
Multidisciplinary teams that include
community pharmacists could
facilitate the provision of
comprehensive patient- and
population-level care. Such teams
could break down barriers that have
historically fragmented health care.
The Ph-AMR would allow
pharmacies to track such
collaborations, functioning as
a pharmacy-level performance
measure and complementing other
measures used by the Pharmacy
Quality Alliance.32
The AMR is currently used by
physicians and managed care
organizations to improve adherence
to evidence-based guidelines and has
shown consistent associations with
symptom control.19–21,24,30 Guided by
the AMR and motivated by deep
disparities across our community,4
we developed the Ph-AMR as a means
of harnessing geographic variation to
inform allocation of resources to
those pharmacies and areas in most
need of improvement.33,34 The
Ph-AMR could identify pharmacies
that are underdispensing controller
medications while also facilitating
a deeper understanding among
pharmacies of their population in
ways that would prompt the design of
innovative interventions. In
partnership with hospitals,
pharmacies may also use underlying
asthma utilization rates to highlight
high-risk communities. Pharmacies
could then more aggressively provide
medication delivery or counseling
services, flag patients who refill
a disproportionate number of rescue
medications compared with
controllers, or more regularly
communicate with physicians
regarding those patients who do not
seem to be responding to current
therapy. Such pharmacy-driven
asthma intervention programs have
been met with success.22,35,36 One
program in Asheville, North Carolina,
focused on targeted asthma
education, scheduled consultations,
and pharmacy-led monitoring and led
to improvements in asthma control
and reductions in asthma
utilization.22
Identification of problem spots,
targeting of resources, and tracking of
performance are all especially
relevant with the goal of improved
population health and contained cost.
Health care delivery organizations
would benefit from a deeper
understanding of where interventions
could be put in place that favor
chronic prevention over response to
acute exacerbation.37 As Hacker and
Walker note, population health
requires an enhanced “capacity to
assess, monitor, and prioritize”
impactful risk factors.17 This capacity
is augmented by using existing data,
such as that kept by pharmacies, in
innovative and additive ways. The
Ph-AMR and the following of fill
patterns enables physicians, pharmacists,
TABLE 2 Ph-AMR Quintile and Associations With Census Tract–Level Covariatesa and the Primary









0.38–0.48 19.6 18.9 17.3 28.4
0.49–0.51 18.8 15.2 10.8 22.4
0.53–0.56 19.9 11.8 8.0 10.0
0.56–0.59 20.3 5.9 5.9 10.4
0.59–0.66 20.5 5.9 5.0 7.1
a Weighted averages, using population denominators available from the US Census.
b P # .05 for relationship between Ph-AMR and census tract–level variable.
c P , .01 for relationship between Ph-AMR and census tract–level variable.
FIGURE 3
Linear regression fit plot for Ph-AMR and asthma-related emergent utilization rate for the census tract
in which the pharmacy is located. Unadjusted linear regression; R2 for this model is 0.45 (P = .0001).
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and accountable care organizations to
continuously monitor actionable
trends. Such measurement strategies
could highlight areas where health
promotion could be prioritized;
pharmacies could focus on
dispensing controller medications as
a means toward proactive
prevention, toward appropriate
anticipation of seasonal morbidity
peaks rather than as a reaction to
seasonal variation in demand.
Moreover, the Ph-AMR could be used
to identify high-risk areas and then
the patient-level AMR could be used,
in concert, to track specific high-risk
patients.
This study is not without limitations.
First, analyses relied on a single
pharmacy chain’s administrative
data. Nevertheless, included
pharmacies have ∼45% of the
market share and are well
distributed across the county.
Second, those that use this pharmacy
chain may differ from those who do
not. Data from other chains and in
other regions are needed to validate
and generalize our findings. Third,
we do not know the true market for
each individual pharmacy. We
believe the census tract is
a conservative estimate of market
share. Still, a family’s choice of
pharmacy may be independently
related to where they live and/or
where they seek medical care.
Fourth, we believe that included
covariates address some but likely
not all confounding. The number of
pharmacies included in the analyses
precluded us from adjusting for
many more variables. Residual
factors such as health-care-seeking
behaviors, exposure to tobacco
smoke, exposure to indoor and
outdoor pollutants or allergens, and
influenza rates all may be associated
with the outcome, but such data
were not available to us. We did not
adjust for race/ethnicity given that
we expected race/ethnicity was
likely related to both predictor and
outcome through the other assessed
covariates (eg, poverty, access).3
FIGURE 4
Time-series illustrating absolute number of all controller and rescue medication fills by week over
a 2-year period for (A) all pharmacies, (B) pharmacies within a census tract with emergent
utilization rate below the median; and (C) pharmacies within a census tract with emergent utili-
zation rate above the median. avg, average.
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Fifth, the data sets used were distinct
and were unable to be matched at
the patient level. Finally, the sample
through which we calculated our
population-level outcome was drawn
from a single hospital; we cannot
account for children who seek care
elsewhere. However, the vast
majority of in-county children use
CCHMC for hospital care; we expect
that a similarly high percentage
makes use of our emergency
facilities.
In the future, we will test the Ph-AMR
against additional outcomes
(eg, acute asthma-related primary
care visits). We also will assess
whether an analogous medication
ratio can be developed at the
community-level using insurance
claims data. Additionally, we expect to
translate our findings into the
implementation and evaluation of
targeted interventions aimed at
increasing controller medication fills
in those areas at highest risk.
CONCLUSIONS
This newly developed Ph-AMR was
strongly associated with population-
level childhood asthma morbidity.
Pharmacies located in high-utilizing
census tracts were more likely to
dispense rescue medications than
controller medications. Collaborative
relationships among physicians,
community pharmacists, and patients
(and families) have the potential to
promote testable interventions aimed
at reducing asthma morbidity and
cross-community disparities. In this
way, pharmacies could play
a substantial role as a population
health leverage point for assessing
and improving asthma control within
a community.
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